Across TCGA pan-cancer cohorts, ADAM3A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ADAM3A data layer compared with 13 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ADAM3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADAM3A expression acts as an unfavorable survival marker.

UCEC and SARC are the cancer types where ADAM3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SARC	DFS	Median	All	0.081	0.632	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ADAM3A tumor-vs-normal RNA expression · all ADAM3A data types